3. Significant Strategic Drug Collaborations - Related Parties |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2019 | |||
| Significant Strategic Drug Collaborations - Related Parties | |||
| Significant Strategic Drug Collaborations - Related Parties |
The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd., Serum Institute of India (“Serum Institute”), its controlling stockholder PJSC Pharmsynthez (“Pharmsynthez”) and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2019. No amounts were recognized as revenue related to these agreements during the three months ended March 31, 2019 or 2018. |